Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1195

1.

Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.

Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M.

Oncoimmunology. 2017 Dec 26;7(3):e1397250. doi: 10.1080/2162402X.2017.1397250. eCollection 2018.

2.

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G.

Oncoimmunology. 2017 Nov 27;7(3):e1396402. doi: 10.1080/2162402X.2017.1396402. eCollection 2018.

PMID:
29399395
3.

Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

Xing X, Guo J, Wen X, Ding G, Li B, Dong B, Feng Q, Li S, Zhang J, Cheng X, Guo T, Du H, Hu Y, Wang X, Li L, Li Q, Xie M, Li L, Gao X, Shan F, Li Z, Ying X, Zhou T, Wang J, Ji J.

Oncoimmunology. 2017 Dec 21;7(3):e1356144. doi: 10.1080/2162402X.2017.1356144. eCollection 2018.

PMID:
29399387
4.

An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy.

Westwood JA, Ellis S, Danne J, Johnson C, Oorschot V, Ramm G, Tscharke DC, Davenport AJ, Whisstock JC, Darcy PK, Kershaw MH, Slaney CY.

Oncotarget. 2017 Dec 14;8(70):115215-115229. doi: 10.18632/oncotarget.23215. eCollection 2017 Dec 29.

5.

Prognostic significance of cystatin SN associated nomograms in patients with colorectal cancer.

Li T, Xiong Q, Zou Z, Lei X, Jiang Q, Liu D.

Oncotarget. 2017 Dec 8;8(70):115153-115163. doi: 10.18632/oncotarget.23041. eCollection 2017 Dec 29.

6.

The signature of liver cancer in immune cells DNA methylation.

Zhang Y, Petropoulos S, Liu J, Cheishvili D, Zhou R, Dymov S, Li K, Li N, Szyf M.

Clin Epigenetics. 2018 Jan 18;10:8. doi: 10.1186/s13148-017-0436-1. eCollection 2018.

7.

Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.

Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S.

Oncotarget. 2017 Dec 4;8(67):111836-111846. doi: 10.18632/oncotarget.22912. eCollection 2017 Dec 19.

8.

Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy.

Bernal-Estévez DA, García O, Sánchez R, Parra-López CA.

BMC Cancer. 2018 Jan 15;18(1):77. doi: 10.1186/s12885-017-3982-1.

9.

CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.

Ziai J, Gilbert HN, Foreman O, Eastham-Anderson J, Chu F, Huseni M, Kim JM.

PLoS One. 2018 Jan 10;13(1):e0190158. doi: 10.1371/journal.pone.0190158. eCollection 2018.

10.

Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.

Moschetta M, Uccello M, Kasenda B, Mak G, McClelland A, Boussios S, Forster M, Arkenau HT.

Biomed Res Int. 2017;2017:1506824. doi: 10.1155/2017/1506824. Epub 2017 Nov 28.

11.

Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.

Mirzaei HR, Rodriguez A, Shepphird J, Brown CE, Badie B.

Front Immunol. 2017 Dec 22;8:1850. doi: 10.3389/fimmu.2017.01850. eCollection 2017. Review.

12.

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr..

J Immunol. 2018 Jan 15;200(2):432-442. doi: 10.4049/jimmunol.1701269. Review.

PMID:
29311385
13.

A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Finn OJ.

J Immunol. 2018 Jan 15;200(2):385-391. doi: 10.4049/jimmunol.1701302. Review.

PMID:
29311379
14.

Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer.

Jarosch A, Sommer U, Bogner A, Reißfelder C, Weitz J, Krause M, Folprecht G, Baretton GB, Aust DE.

Oncoimmunology. 2017 Nov 7;7(2):e1393133. doi: 10.1080/2162402X.2017.1393133. eCollection 2018.

PMID:
29308324
15.

Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors.

Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H, Debets R.

Oncoimmunology. 2017 Oct 11;7(1):e1378842. doi: 10.1080/2162402X.2017.1378842. eCollection 2017.

16.

A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.

Hijikata Y, Okazaki T, Tanaka Y, Murahashi M, Yamada Y, Yamada K, Takahashi A, Inoue H, Kishimoto J, Nakanishi Y, Oda Y, Nakamura Y, Tani K.

PLoS One. 2018 Jan 2;13(1):e0187878. doi: 10.1371/journal.pone.0187878. eCollection 2018.

17.

Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches.

Maciejko L, Smalley M, Goldman A.

J Mol Biomark Diagn. 2017 Sep;8(5). pii: 350. doi: 10.4172/2155-9929.1000350. Epub 2017 Jun 28.

18.

Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival.

Sekar RR, De La Calle CM, Patil D, Holzman SA, Baum Y, Sheikh U, Huang JH, Osunkoya AO, Pollack BP, Kissick HT, Ogan K, Master VA.

Asian J Urol. 2016 Apr;3(2):75-81. doi: 10.1016/j.ajur.2016.02.001. Epub 2016 Feb 26.

19.

A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity.

Tian H, Shi G, Wang Q, Li Y, Yang Q, Li C, Yang G, Wu M, Xie Q, Zhang S, Yang Y, Xiang R, Yu D, Wei Y, Deng H.

Signal Transduct Target Ther. 2016 Nov 18;1:16025. doi: 10.1038/sigtrans.2016.25. eCollection 2016.

20.

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V, Cristofanilli M, Giles F.

Oncotarget. 2017 Aug 1;8(59):100863-100898. doi: 10.18632/oncotarget.19809. eCollection 2017 Nov 21. Review.

Supplemental Content

Support Center